Senedd

Yr heriau'n wynebu Rhun ap Iorwerth cyn yr etholiadau nesaf

Retrieved on: 
Monday, July 17, 2023
Senedd, AR, SNP, Fel, OND, Synthetic rubber, Cardboard, Liquor, European

Blaenoriaeth ddi-oed, sydd wedi ei chydnabod gan ap Iorwerth wrth ddod i'r swydd, yw gweithredu 82 argymhelliad yn yr adroddiad.

Key Points: 
  • Blaenoriaeth ddi-oed, sydd wedi ei chydnabod gan ap Iorwerth wrth ddod i'r swydd, yw gweithredu 82 argymhelliad yn yr adroddiad.
  • Er mwyn sicrhau enillion yn yr etholiadau hynny, mae gofyn am fwy na diwygio trefnidaethol a blaengynllunio etholiadol trylwyr.
  • Yr awgrym yn ôl yr arolygon barn ydy taw cyfyngedig fydd unrhyw ennill tir yn yr etholiad cyffredinol nesaf.

Annibyniaeth i Gymru

    • Drwy wneud hynny, roedd yn mabwysiadu yr un math o strategaeth â llawer o bleidiau a mudiadau o blaid annibyniaeth ar draws Ewrop.
    • Y casgliad oedd bod galwadau am annibyniaeth wedi cynyddu, gyda mwy o bwyslais ar gyflwyno achos cadarnhaol dros greu gwladwriaeth newydd.
    • Eto'i gyd, lleiafrif o bleidleiswyr sy'n cefnogi annibyniaeth gyda diwygio cyfansoddiadol yn isel ar y rhestr o faterion sy'n bwysig i bobl.

Esiampl yr Alban

    • Dangosodd methiant ymdrechion Plaid Genedlaethol yr Alban (yr SNP) i sicrhau'r hawl gyfreithiol i gynnal refferendwm arall ar annibyniaeth nad oes llwybr hawdd i'r rhai sydd am adael y DG.
    • A hynny er gwaetha'r trafferthion sy'n wynebu Llywodraeth Cymru yn y meysydd sydd o dan ei adain fel y gwasanaeth iechyd.
    • Wrth gwrs, y tebygrwydd hefyd yw y bydd Llafur Cymru yn ymladd yn yr etholiad nesaf i'r Senedd gydag arweinydd newydd wrth y llyw.
    • Bydd natur yr ornest yn wahanol hefyd wrth i'r diwygiadau i'r Senedd gael eu rhoi ar waith gan gynyddu'r nifer o aelodau o 60 i 96 a chyflwyno system etholiadol newydd.

Plaid Cymru's new leader faces tough challenges ahead of next elections

Retrieved on: 
Monday, July 17, 2023
Plaid Cymru, Plaid, Culture, Rhun ap Iorwerth, Policy, Iorwerth, The National (Scotland), Research, COVID, Movement, Government, Bullying, Intention, Time, SNP, NHS, Welsh Labour, Drug, Senedd, Welsh, Labour

Rhun ap Iorwerth was appointed as Plaid Cymru’s new leader mid-June 2023.

Key Points: 
  • Rhun ap Iorwerth was appointed as Plaid Cymru’s new leader mid-June 2023.
  • He replaced Adam Price, who stood down in response to a damaging report which found evidence of a culture of sexual harassment, bullying and misogyny in the party.
  • This is a major undertaking for any political party, but particularly for an organisation which is not large, or especially well-resourced.
  • This is a trend confirmed by its performance in the 2019 general election and the 2021 Senedd election.

Welsh independence

    • In the 2021 Senedd election, Plaid Cymru put its call for Welsh independence front and centre of its campaign and promised to hold a referendum within five years if it became the party of government.
    • But such a strategy misjudged the priorities of Welsh voters at the time, which was recovery from the COVID pandemic, rather than major constitutional change.
    • Welsh independence is still only supported by a minority of voters.

Scotland’s example

    • Many of those who do support Welsh independence, are also Labour voters.
    • And there is no sign that they are willing to ditch their allegiance and switch to supporting Plaid Cymru instead.
    • This is in spite of the difficulties that the Welsh Labour-led Welsh government is facing in the areas it is responsible for, such as the NHS.
    • In having to compete against such an opponent, Rhun ap Iorwerth’s Plaid Cymru faces an electoral challenge that is unique among Europe’s pro-independence parties.

NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales

Retrieved on: 
Wednesday, July 13, 2022
Professional corporation, Product, Sale, NHS, U.S. Securities and Exchange Commission, Capsule, News, Diabetes, Health care, National Health Service, Risk, Patient, Abolish the Welsh Assembly Party, Adult, Review, NICE, GLOBE, Union, Government, Welsh Government sponsored bodies, Degenerative disease, Cardiovascular disease, Medication package insert, Senedd, Private Securities Litigation Reform Act, Welsh, EUR, File, HTA, CV, United Arab Emirates, Research, Annual report, Eicosapentaenoic acid, Medicine, NASDAQ, USD, Health insurance, Pharmaceutical industry, Amarin Corporation

DUBLIN, Ireland and BRIDGEWATER, N.J., July 13, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that NICE has issued its final guidance recommending VAZKEPA® (icosapent ethyl) for reimbursement and use across the National Health Service (NHS) in England and Wales to help reduce the risk of major CV events in high-risk statin-treated patients with eCVD, at a price of £144.21 per 120 soft capsules (i.e. 30 day supply; the equivalent of approximately 171 EUR or 172 USD*).

Key Points: 
  • This announcement marks a major milestone for Amarin globally and in the UK, as following final guidance, all local NHS formularies in England and Wales will need to make VAZKEPA available within 90 and 60 days, respectively.
  • The publication of the final guidance supports the growing recognition of VAZKEPAs clinical benefits.
  • Based on the collaborative relationship between the Welsh Government and the All-Wales Medicines Strategy Group (AWMSG), the final NICE guidance will also be implemented across the NHS in Wales, in line with the devolved powers of the Welsh Assembly.
  • In April 2021 marketing authorization for VAZKEPA (icosapent ethyl) was granted in Great Britain (applying to England, Scotland and Wales).